News Releases

Date Title and Summary Additional Formats
Toggle Summary Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year
Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO --(BUSINESS WIRE)--Nov. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2018 and provided an update on its corporate
View HTML
Toggle Summary Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress
SAN DIEGO --(BUSINESS WIRE)--Oct. 24, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new
View HTML
Toggle Summary Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
SAN DIEGO --(BUSINESS WIRE)--Oct. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in
View HTML
Toggle Summary Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s novel once-weekly
View HTML
Toggle Summary Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
SAN DIEGO --(BUSINESS WIRE)--Sep. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and
View HTML
Toggle Summary FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
View HTML
Toggle Summary Cidara Therapeutics to Present at Two Upcoming Investor Conferences
SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two
View HTML
Toggle Summary Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors
Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel
View HTML
Toggle Summary Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018
Presentations will highlight data demonstrating the broad clinical utility, safety and potency of rezafungin to fight invasive fungal infections SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
View HTML
Toggle Summary Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting
Data highlight potential of Cloudbreak immunotherapy candidates for the treatment of multi-drug resistant Gram-negative bacterial infections SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
SAN DIEGO , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2018 and provided an update on its corporate activities
View HTML
Toggle Summary Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences
Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
View HTML
Toggle Summary Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections
Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO --(BUSINESS WIRE)--May 23, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel
View HTML
Toggle Summary Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections
New Partnership to Jointly Conduct Preclinical Development of Cidara’s Cloudbreak Antibody-Drug Conjugates SAN DIEGO --(BUSINESS WIRE)--May 21, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that
View HTML
Toggle Summary Cidara Therapeutics Announces Offering of Common Stock and Warrants
SAN DIEGO , May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with certain investors providing for the purchase and
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and provided an update on its corporate activities and
View HTML
Toggle Summary Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus SAN DIEGO --(BUSINESS WIRE)--Apr. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing
View HTML
Toggle Summary Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
Additional data and analyses from  STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN DIEGO , March 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc.
View HTML
Toggle Summary Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin
Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to start mid-2018 Company to host conference call today at 8:00 a.m. ET / 5:00 a.m.
View HTML
Toggle Summary Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting
SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted for presentation at the 44 th Annual Meeting of the European
View HTML
Toggle Summary Cidara Announces Appointment of Chrysa Mineo as Independent Director
SAN DIEGO , March 01, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of Chrysa Mineo to the company’s board of directors. Ms.
View HTML
Toggle Summary Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2017 , and provided an update on its
View HTML
Toggle Summary Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
Data Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections in Immunocompromised Patients SAN DIEGO , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including
View HTML
Toggle Summary Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections
Authors Highlight How New Options Can be Used to Augment Antifungal Treatment and Prophylaxis Strategies SAN DIEGO , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a
View HTML